Hepatic encephalopathy

Wissam Bleibel, Abdullah M S Al-Osaimi, Wissam Bleibel, Abdullah M S Al-Osaimi

Abstract

Chronic liver disease and cirrhosis affect hundreds of millions of patients all over the world. The majority of patients with cirrhosis will eventually develop complications related to portal hypertension. One of these recurrent and difficult to treat complications is hepatic encephalopathy. Studies have indicated that overt hepatic encephalopathy affects 30 to 45% of patients with cirrhosis and a higher percentage may be affected by minimal degree of encephalopathy. All of these factors add to the impact of hepatic encephalopathy on the healthcare system and presents a major challenge to the gastroenterologist, hospitalist and primary care physician.

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Classification of hepatic encephalopathy according to the working party at the 11th World Congress of Gastroenterology, Vienna, 1998.[6]
Figure 2
Figure 2
Algorithm for evaluation and treatment of HE

References

    1. Sanyal AJ, Mullen KD, Bass NM. The treatment of hepatic encephalopathy in the cirrhotic patient. Gastroenterol Hepatol (N Y) 2010;6(4 Suppl 8):1–12.
    1. Bismuth M, Funakoshi N, Cadranel JF, Blanc P. Hepatic encephalopathy: From pathophysiology to therapeutic management. Eur J Gastroenterol Hepatol. 2011;23:8–22.
    1. Butterworth RF. Editorial: Rifaximin and minimal hepatic encephalopathy. Am J Gastroenterol. 2011;106:317–8.
    1. Seyan AS, Hughes RD, Shawcross DL. Changing face of hepatic encephalopathy: Role of inflammation and oxidative stress. World J Gastroenterol. 2010;16:3347–57.
    1. McPhail MJ, Bajaj JS, Thomas HC, Taylor-Robinson SD. Pathogenesis and diagnosis of hepatic encephalopathy. Expert Rev Gastroenterol Hepatol. 2010;4:365–78.
    1. Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2010;7:515–25.
    1. Blauenfeldt RA, Olesen SS, Hansen JB, Graversen C, Drewes AM. Abnormal brain processing in hepatic encephalopathy: Evidence of cerebral reorganization? Eur J Gastroenterol Hepatol. 2010;22:1323–30.
    1. Wright G, Noiret L, Olde Damink SW, Jalan R. Interorgan ammonia metabolism in liver failure: The basis of current and future therapies. Liver Int. 2011;31:163–75.
    1. Chen SJ, Wang LJ, Zhu Q, Cai JT, Chen T, Si JM. Effect of H pylori infection and its eradication on hyperammo-nemia and hepatic encephalopathy in cirrhotic patients. World J Gastroenterol. 2008;14:1914–8.
    1. Bessman SP. Ammonia metabolism. Rev Neuropsiquiatr. 1964;27:323–6.
    1. Lockwood AH. Positron emission tomography in the study of hepatic encephalopathy. Metab Brain Dis. 1998;13:303–9.
    1. Montgomery JY, Bajaj JS. Advances in the evaluation and management of minimal hepatic encephalopathy. Curr Gastroenterol Rep. 2011;13:26–33.
    1. Reddy PV, Rama Rao KV, Norenberg MD. Inhibitors of the mitochondrial permeability transition reduce ammonia-induced cell swelling in cultured astrocytes. J Neurosci Res. 2009;87:2677–85.
    1. Mardini H, Smith FE, Record CO, Blamire AM. Magnetic resonance quantification of water and metabolites in the brain of cirrhotics following induced hyperammonaemia. J Hepatol. 2011;54:1154–60.
    1. Cordoba J, Minguez B. Hepatic encephalopathy. Semin Liver Dis. 2008;28:70–80.
    1. Balata S, Olde Damink SW, Ferguson K, Marshall I, Hayes PC, Deutz NE, et al. Induced hyperammonemia alters neuropsychology, brain MR spectroscopy and magnetization transfer in cirrhosis. Hepatology. 2003;37:931–9.
    1. Cardelli-Cangiano P, Cangiano C, James JH, Ceci F, Fischer JE, Strom R. Effect of ammonia on amino acid uptake by brain microvessels. J Biol Chem. 1984;259:5295–300.
    1. Grippon P, Le Poncin Lafitte M, Boschat M, Wang S, Faure G, Dutertre D, et al. Evidence for the role of ammonia in the intracerebral transfer and metabolism of tryptophan. Hepatology. 1986;6:682–6.
    1. James JH, Ziparo V, Jeppsson B, Fischer JE. Hyperammonaemia, plasma aminoacid imbalance, and blood-brain aminoacid transport: A unified theory of portal-systemic encephalopathy. Lancet. 1979;2:772–5.
    1. Zieve FJ, Zieve L, Doizaki WM, Gilsdorf RB. Synergism between ammonia and fatty acids in the production of coma: Implications for hepatic coma. J Pharmacol Exp Ther. 1974;191:10–6.
    1. Zieve L, Doizaki WM, Zieve J. Synergism between mercaptans and ammonia or fatty acids in the production of coma: A possible role for mercaptans in the pathogenesis of hepatic coma. J Lab Clin Med. 1974;83:16–28.
    1. Riggio O, Mannaioni G, Ridola L, Angeloni S, Merli M, Carlà V, et al. Peripheral and splanchnic indole and oxindole levels in cirrhotic patients: A study on the pathophysiology of hepatic encephalopathy. Am J Gastroenterol. 2010;105:1374–81.
    1. Moroni F, Carpenedo R, Venturini I, Baraldi M, Zeneroli ML. Oxindole in pathogenesis of hepatic encephalopathy. Lancet. 1998;351:1861.
    1. Benten D, Schulze zur Wiesch J, Sydow K, Koops A, Buggisch P, Böger RH, et al. The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS) BMC Gastroenterol. 2011;11:107.
    1. Lin CY, Tsai IF, Ho YP, Huang CT, Lin YC, Lin CJ, et al. Endotoxemia contributes to the immune paralysis in patients with cirrhosis. J Hepatol. 2007;46:816–26.
    1. Montoliu C, Piedrafita B, Serra MA, del Olmo JA, Urios A, Rodrigo JM, et al. IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy. J Clin Gastroenterol. 2009;43:272–9.
    1. Shawcross DL, Sharifi Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, et al. Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol. 2011;54:640–9.
    1. Williams R. Introduction: The burden, pathophysiology and management of hepatic encephalopathy. Aliment Pharmacol Ther. 2007;25(Suppl 1):1–2.
    1. Wasmuth HE, Kunz D, Yagmur E, Timmer-Stranghöner A, Vidacek D, Siewert E, et al. Patients with acute on chronic liver failure display “sepsis-like” immune paralysis. J Hepatol. 2005;42:195–201.
    1. Wright G, Jalan R. Ammonia and inflammation in the pathogenesis of hepatic encephalopathy: Pandora's box? Hepatology. 2007;46:291–4.
    1. Ahboucha S, Jiang W, Chatauret N, Mamer O, Baker GB, Butterworth RF. Indomethacin improves locomotor deficit and reduces brain concentrations of neuroinhibitory steroids in rats following portacaval anastomosis. Neurogastroenterol Motil. 2008;20:949–57.
    1. Lozeva V, Tuomisto L, Sola D, Plumed C, Hippeläinen M, Butterworth R, et al. Increased density of brain histamine H (1) receptors in rats with portacaval anastomosis and in cirrhotic patients with chronic hepatic encephalopathy. Hepatology. 2001;33:1370–6.
    1. Cordoba J, Cabrera J, Lataif L, Penev P, Zee P, Blei AT. High prevalence of sleep disturbance in cirrhosis. Hepatology. 1998;27:339–45.
    1. Ahboucha S, Pomier-Layrargues G, Mamer O, Butterworth RF. Increased levels of pregnenolone and its neuroactive metabolite allopregnanolone in autopsied brain tissue from cirrhotic patients who died in hepatic coma. Neurochem Int. 2006;49:372–8.
    1. Cadranel JF, Lebiez E, Di Martino V, Bernard B, El Koury S, Tourbah A, et al. Focal neurological signs in hepatic encephalopathy in cirrhotic patients: An underestimated entity? Am J Gastroenterol. 2001;96:515–8.
    1. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071–81.
    1. Montagnese S, Biancardi A, Schiff S, Carraro P, Carlà V, Mannaioni G, et al. Different biochemical correlates for different neuropsychiatric abnormalities in patients with cirrhosis. Hepatology. 2011;53:558–66.
    1. Conn HO. Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis. 1977;22:541–50.
    1. Sharma P, Agrawal A, Sharma BC, Sarin SK. Prophylaxis of hepatic encephalopathy in acute variceal bleed: A randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol. 2011;26:996–1003.
    1. Blei AT, Cordoba J. Hepatic Encephalopathy. Am J Gastroenterol. 2001;96:1968–76.
    1. Shawcross D, Jalan R. Dispelling myths in the treatment of hepatic encephalopathy. Lancet. 2005;365:431–3.
    1. Mullen KD. The treatment of patients with hepatic encephalopathy: Review of the latest data from EASL 2010. Gastroenterol Hepatol (N Y) 2010;6:1–16.
    1. Nelson DC, McGrew WR, Jr, Hoyumpa AM., Jr Hypernatremia and lactulose therapy. JAMA. 1983;249:1295–8.
    1. Uribe M, Márquez MA, García-Ramos G, Escobedo V, Murillo H, Guevara L, et al. Treatment of chronic portal-systemic encephalopathy with lactose in lactase-deficient patients. Dig Dis Sci. 1980;25:924–8.
    1. Mortensen PB. The effect of oral-administered lactulose on colonic nitrogen metabolism and excretion. Hepatology. 1992;16:1350–6.
    1. Maclayton DO, Eaton-Maxwell A. Rifaximin for treatment of hepatic encephalopathy. Ann Pharmacother. 2009;43:77–84.
    1. Lawrence KR, Klee JA. Rifaximin for the treatment of hepatic encephalopathy. Pharmacotherapy. 2008;28:1019–32.
    1. Mantry PS, Munsaf S. Rifaximin for the treatment of hepatic encephalopathy. Transplant Proc. 2010;42:4543–7.
    1. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology. 2004;39:1441–9.
    1. Bajaj JS, Saeian K, Christensen KM, Hafeezullah M, Varma RR, Franco J, et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol. 2008;103:1707–15.
    1. Shukla S, Shukla A, Mehboob S, Guha S. Meta-analysis: The effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Aliment Pharmacol Ther. 2011;33:662–71.
    1. Gentile S, Guarino G, Romano M, Alagia IA, Fierro M, Annunziata S, et al. A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol. 2005;3:184–91.
    1. Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Görtelmeyer R, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo-controlled, double-blind study. Hepatology. 1997;25:1351–60.
    1. Kircheis G, Wettstein M, Dahl S, Häussinger D. Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy. Metab Brain Dis. 2002;17:453–62.
    1. Batshaw ML, Walser M, Brusilow SW. Plasma alpha-ketoglutarate in urea cycle enzymopathies and its role as a harbinger of hyperammonemic coma. Pediatr Res. 1980;14:1316–9.
    1. Bemeur C, Desjardins P, Butterworth RF. Role of nutrition in the management of hepatic encephalopathy in end-stage liver failure. J Nutr Metab. 2010;2010:489823.
    1. Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, Bellomo G, Belloni G, et al. Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: An Italian multicentre double-blind, placebo-controlled, cross-over study. Hepatology. 1998;28:374–8.
    1. Barbaro G, Di Lorenzo G, Soldini M, Marziali M, Bellomo G, Belloni G, et al. Flumazenil for hepatic coma in patients with liver cirrhosis: An Italian multicentre double-blind, placebo-controlled, crossover study. Eur J Emerg Med. 1998;5:213–8.
    1. Zeneroli ML. Hepatic encephalopathy. Experimental studies in a rat model of fulminant hepatic failure. J Hepatol. 1985;1:301–11.
    1. Yoshida Y, Higashi T, Nouso K, Nakatsukasa H, Nakamura SI, Watanabe A, et al. Effects of zinc deficiency/zinc supplementation on ammonia metabolism in patients with decompensated liver cirrhosis. Acta Med Okayama. 2001;55:349–55.
    1. Coughlan J, Hamlin PJ, Ford AC. Effect of oral zinc in hepatic encephalopathy remains unclear. Aliment Pharmacol Ther. 2010;32:1405–6. author reply 1406-7.
    1. Takuma Y, Nouso K, Makino Y, Hayashi M, Takahashi H. Clinical trial: Oral zinc in hepatic encephalopathy. Aliment Pharmacol Ther. 2010;32:1080–90.
    1. Kato T, Uematsu T, Nishigaki Y, Sugihara J, Tomita E, Moriwaki H. Therapeutic effect of balloon-occluded retrograde transvenous obliteration on portal-systemic encephalopathy in patients with liver cirrhosis. Intern Med. 2001;40:688–91.
    1. Cordoba J, López-Hellín J, Planas M, Sabín P, Sanpedro F, Castro F, et al. Normal protein diet for episodic hepatic encephalopathy: Results of a randomized study. J Hepatol. 2004;41:38–43.
    1. Guevara M, Baccaro ME, Gómez-Ansón B, Frisoni G, Testa C, Torre A, et al. Cerebral magnetic resonance imaging reveals marked abnormalities of brain tissue density in patients with cirrhosis without overt hepatic encephalopathy. J Hepatol. 2011;55:564–73.
    1. Bajaj JS, Schubert CM, Heuman DM, Wade JB, Gibson DP, Topaz A, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology. 2010;138:2332–40.
    1. Riggio O, Ridola L, Pasquale C, Nardelli S, Pentassuglio I, Moscucci F, et al. Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy. Clin Gastroenterol Hepatol. 2011;9:181–3.
    1. Garcia-Martinez R, Rovira A, Alonso J, Jacas C, Simón-Talero M, Chavarria L, et al. Hepatic encephalopathy is associated with posttransplant cognitive function and brain volume. Liver Transpl. 2011;17:38–46.
    1. Huang E, Esrailian E, Spiegel BM. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - A decision analysis. Aliment Pharmacol Ther. 2007;26:1147–61.
    1. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: Final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716–21.
    1. Al-Osaimi A, Quatrara B, Melo I, Romeo LM, Berg CL, Caldwell SH, et al. In-patient hepatic encephalopathy protocol improves in-patient outcome measures: Interim analysis. Hepatology. 2009;50:446A.
    1. Bleibel W, Quatrara B, Irene Melo, Romeo LM, Berg CL, Caldwell SH, et al. Implementing a treatment protocol reduces inpatient cost of hepatic encephalopathy. Gastroenterology. 2011:140.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren